Deciphering the immune-modulating effect of Staphylococcus aureus protein A (SpA) on the functional antibody response
Deciphering the immune-modulating effect of Staphylococcus aureus protein A (SpA) on the functional antibody response
批准号:
2594575
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2021
资助国家:
英国
项目状态:
未结题
起止时间:
2021 至 --
中文摘要
点击翻译按钮获取中文摘要
英文摘要
While Staphylococcus aureus is commonly found as part of the human commensal flora it is also a major opportunistic pathogen causing significant illness and burden on healthcare systems. The increasing incidence of antimicrobial resistant infection including methicillin-resistant Staphylococcus aureus (MRSA) and the failure of effective prevention approaches means that it remains a high-priority target for the development of new therapeutics and vaccines [1].Human immune responses to S. aureus often appear dysregulated due to an array of immune-modulator bacterial virulence factors. These factors block immune cell chemotaxis, complement activation, phagocytic uptake and oxidative killing, and facilitate pathogen replication. This results in disruption of normal B and T cell function, preventing the establishment of otherwise protective immune responses [2]. Central to the disruption of B cell survival and function is S. aureus protein A (SpA), an immunoglobulin (Ig)-binding virulence factor, which subsequently impairs the humoral response. As a cell wall-associated protein, SpA is either expressed on the bacterial surface or secreted. By sequestering immunoglobulin through the Fc portion, SpA causes disruption of opsonophagocytosis resulting in bacterial persistence. Another key function of SpA is to impair the B cell response by binding the Fab region of VH3-type B cell receptor and acting as a superantigen. In mice, B cells targeted by this superantigen initially undergo massive activation, followed by apoptosis and cell death [3]. SpA is also associated with the transient extrafollicular expansion of short-lived VH3-biased B cells followed by reduction of protective secondary anti-S. aureus antibody response and of the pool of bone marrow-resident long-lived antigen-specific plasma cells [4]. Moreover, analysis of human B cells revealed a similar VH3-dominant response both during natural infection and in the memory compartment of healthy individuals [5, 6]. It is currently unknown to what extent these effects are relevant to the functional human response to infection and what is the impact of this biased antibody response to the establishment of protective defenses. The aim of this PhD project is to understand the immune-modulating effect of S. aureus protein A on the functional response to infection in humans. Using clinical samples obtained from healthy donors, individuals recovering from S. aureus infection and other sources, you will characterize the mechanisms underlying SpA-mediated evasion of a functional antibody response. Understanding this mechanism will be vital to deciphering the virulence of S. aureus and other microorganisms.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
登录
查看更多内容
声致离子电流促进小胶质细胞M2极化阻断再生神经瘢痕退变免疫机制
-
批准号:82371973
-
项目类别:面上项目
-
资助金额:48.00万元
-
批准年份:2023
-
负责人:孙迪
-
依托单位:
转运蛋白RCP调控巨噬细胞脂肪酸氧化参与系统性红斑狼疮发病的机制研究
-
批准号:82371798
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:叶俊娜
-
依托单位:
基于FCER1G基因介导免疫反应探讨迟发性聋与认知障碍相关性的机制研究
-
批准号:82371141
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:陈颖
-
依托单位:
CD27-CD28-CD8+T细胞调控儿童肝脏移植免疫耐受形成的作用和机制
-
批准号:82371791
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:刘永波
-
依托单位:
T细胞受体NRP1作为新型免疫检查点在去势抵抗性前列腺癌中的作用机制研究
-
批准号:32100631
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:刘飞
-
依托单位:
抑制FGF19/FGFR4信号通路促进肺鳞癌细胞焦亡及免疫增效的机制研究
-
批准号:32100565
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:李凡
-
依托单位:
间充质干细胞通过CD73/CD39/腺苷-PI3K/Akt-Nrf2信号轴调节CD4+IL-10+IFN-γ+T细胞分化减弱GVHD机制研究
-
批准号:32070781
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:栾希英
-
依托单位:
自噬基因Epg5在诺如病毒感染过程中的作用
-
批准号:32070745
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:路群
-
依托单位:
C9ORF72-SMCR8复合物在小胶质细胞中的功能及其介导的炎症反应
-
批准号:32070743
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:杨玫
-
依托单位:
MET通过MTOR介导的自噬调节肝癌免疫原性和治疗抗性的作用及机制研究
-
批准号:31970696
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2019
-
负责人:黄星
-
依托单位: